Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Cogent Biosciences

Status and phase: Terminated; Phase 1

Conditions: Multiple Myeloma in Relapse; Multiple Myeloma; Refractory Multiple Myeloma

Treatments: Biological: ACTR087; Biological: SEA-BCMA

Study type: Interventional

Funder types: Industry

Identifiers

NCT03266692

ATTCK-17-01

Details and patient eligibility

About

This is a phase 1, multi-center, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma.

Enrollment: 15 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed written informed consent obtained prior to study procedures
• Histologically- or cytologically-confirmed relapsed or refractory multiple myeloma (MM) with measurable disease
• Must have received at least 3 prior lines of therapy to include treatment with a proteasome inhibitor (eg, bortezomib, carfilzomib, or ixazomib) and an immunomodulatory agent (eg, lenalidomide, pomalidomide) unless double-refractory to both; and a hematopoietic stem cell transplant (HSCT), for those subjects considered HSCT-eligible.
• Quantitative serum IgG levels for subjects with IgG MM must not exceed the institutional upper limit of normal (ULN)
• ECOG 0 or 1
• Life expectancy of at least 6 months
• Absolute neutrophil (ANC) count greater than 1000/ µL
• Platelet count greater than 50,000/µL
• Estimated GFR >30mL/min/1.73m2

Exclusion criteria

• Known active central nervous system (CNS) involvement by MM

• Systemic rheumatic or autoimmune diseases or acute or chronic infections

• Uncontrolled thromboembolic events or recent severe hemorrhage

• Subjects who are currently using more than 5mg/day of prednisone (or an equivalent glucocorticoid exceeding physiologic replacement levels)

• Prior treatment as follows:

  • T cell-directed antibody therapy (eg. Alemtuzumab, anti-thymocyte globulin) within 6 months of enrollment
  • Any prior myeloma-directed therapy including cytotoxic chemotherapy, biologic therapy, or radiotherapy within 2 weeks of enrollment
  • Any mAb or other protein therapeutic containing Fc-domains within 4 weeks of enrollment
  • Experimental agents within 3 half-lives prior to enrollment, unless progression is documented on therapy
  • Prior BCMA-directed investigational agents at any time
  • Prior cell or gene therapy, excluding transfers of genetically unmodified autologous cells (eg. Hematopoietic stem cell transplantation), at any time; or prior allogeneic HSCT at any time

• Pregnant or breastfeeding

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

15 participants in 1 patient group

ACTR087 in combination with SEA-BCMA

Experimental group

Treatment:

Biological: ACTR087

Biological: SEA-BCMA